Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT

Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Technical Presentation (November 2012)

12 slides from Sagimet Biosciences Inc. - Series A's technical presentation, Nov 11, 2012

  1. Slide 1: Potent HCV Antiviral Activity by Inhibiting Fatty Acid Synthase

    Slide 1: Potent HCV Antiviral Activity by Inhibiting Fatty Acid Synthase

    Potent HCV Antiviral November 11, Activity by Inhibiting Fatty 2012 AASLD Acid Synthase George Kemble, PhD CSO

  2. Slide 2: Drug Profile: Rationale & Approach

    Slide 2: Drug Profile: Rationale & Approach

    Drug Profile: Rationale & Approach • Unique mechanism of action to enable the following: – Pan genotype antiviral activity – Activity against other classes of drug resistant HCV mutants – Well tolerated – High barrier to resistance • Approach – Identify a cellular protein that is: • required for HCV

  3. Slide 3: Fatty Acid Synthase (FASN)

    Slide 3: Fatty Acid Synthase (FASN)

    Fatty Acid Synthase (FASN) • Large, homodimer FASN • Multiple enzymatic domains Acetyl-CoA + 7 Malonyl-CoA + Palmitate ATP, NADPH Other fatty Diglycerides acids & complex & lipids Triglycerides Post- translational modifications (eg NS4b) Adult mice lacking liver FASN are normal Maier, et al. Science

  4. Slide 4: HCV Depends on the FASN Pathway

    Slide 4: HCV Depends on the FASN Pathway

    HCV Depends on the FASN Pathway FASN and/or its product interact with HCV at multiple points of the viral replication cycle Viral Entry RNA Replication Yang, et al, Hepatol. (2008) Virus Assembly and Exit Yu, et al, J. Virol (2006) Sakamoto, et al. Nat. Chem Biol (2005) Umehara, et al., Biochem & Bi

  5. Slide 5: 3-V Inhibitors Are Potent & Specific

    Slide 5: 3-V Inhibitors Are Potent & Specific

    3-V Inhibitors Are Potent & Specific GT1b Replicon Infectious HCV (Gt2a) Inhibitory (50%) Concentration FASN FASN Enzyme GT1b GT2a Enzyme in vitro in cells Replicon* Virus* 50 nM 40 nM 60 nM 41 nM *No toxicity observed at highest concentration tested (10,000 nM) 5

  6. Slide 6: FASN Inhibition Blocks HCV RNA Replication & Protein Expression

    Slide 6: FASN Inhibition Blocks HCV RNA Replication & Protein Expression

    FASN Inhibition Blocks HCV RNA Replication & Protein Expression Inhibition of HCV RNA Replication % Luciferase Inhibition 100.0 80.0 60.0 40.0 20.0 0.0 48 72 96 3-V FASN Inhibitor Treatment (hrs) NS5a Ab No Drug 6

  7. Slide 7: FASN Inhibition Reduces HCV RNA In Passaged Cell Lines

    Slide 7: FASN Inhibition Reduces HCV RNA In Passaged Cell Lines

    FASN Inhibition Reduces HCV RNA In Passaged Cell Lines 100 (normalized to GAPHD) % HCV RNA Relative to 75 Untreated Cells 50 No Drug Prot. Inhib 3-V FASN Inhib 25 0 0 5 10 15 20 25 Days Post Treatment 7

  8. Slide 8: Targeted Inhibition of FASN

    Slide 8: Targeted Inhibition of FASN

    Targeted Inhibition of FASN Palmitate add-back demonstrates on-target mechanism HCV FASN inhibitor Replicon HCV RNA replication (Luciferase) +/- Palmitate FASN enzymatic activity (palmitate synthesis) 1.5 de novo PMT(response) Response de novo palmitate 3-V inhib. TVB-0002722 3-V inhib. 3-V inhib. +

  9. Slide 9: 3-V FASN inhibitors active against a range of HCV variants

    Slide 9: 3-V FASN inhibitors active against a range of HCV variants

    3-V FASN inhibitors active against a range of HCV variants Median Effectiveness Concentration (µM) Active across genotypes Gt1a Gt1b Gt2 0.06 0.06 0.10 120 % Activity Compared 90 to WT replicon 3-V inhibitor 60 Control Cmpds 30 (DAAs) 0 Active against replicons resistant to other classes of HCV drug

  10. Slide 10: FASN inhibited in rats following oral administration

    Slide 10: FASN inhibited in rats following oral administration

    FASN inhibited in rats following oral administration 150 * * % FASN Activity 125 Harvest Liver 100 Analyze 13C Palmitate 75 12 or 24 hours 50 25 3-V FASN inhibitor Add 13C Acetate Oral gavage 0 (t=0) Tracer Veh 30 60 Veh 30 60 (t=10 or 22 hrs) mpk mpk mpk mpk 12 hr 24 hr post dose post dose P<0.05 M

  11. Slide 11: Profile of 3-V's FASN inhibitors

    Slide 11: Profile of 3-V's FASN inhibitors

    Profile of 3-V’s FASN inhibitors • Attractive compounds with unique mechanism of action – On-target activity confirmed – Potent (EC50’s < 100nM) – Pan genotype antiviral activity – Active against HCV mutants resistant to various classes of DAAs – Well tolerated following multiple day dosing at level

  12. Slide 12: 3-V Biosciences, Inc. Contributors

    Slide 12: 3-V Biosciences, Inc. Contributors

    3-V Biosciences, Inc. Contributors Doug Buckley Marc Evanchik Robert McDowell Stefan Moese Yamini Ohol Johan D. Oslob Visit Poster #1876 Merdad Parsey for additional information Amy K. Patick Mohan Sivaraja Sam Tep Satya Yendluri 12

Source: company website

More decks from Sagimet Biosciences Inc. - Series A

All 34 Sagimet Biosciences Inc. - Series A decks